Innovation

GBS Toxin Receptor

Vanderbilt University
posted on 01/25/2010

-


Innovation Details
 

Detailed Description

Vanderbilt researchers have uncovered a novel finding for the toxin from Group beta-hemolytic Streptococcus bacteria (GBS toxin). This group has shown that the GBS toxin may be used as vascular targeting agent to destroy pathological vasculature present in malignant tumors, atherosclerosis, rheumatoid arthritis and chronic wounds.

Supplemental Documents
VU9861—GBS Toxin Receptor

Inventors
Changlin Fu
Carl Hellerqvist


CONTACT
Janis Elsner
(615) 343-2430
janis.elsner@vanderbilt.edu

File Number: MKT9861  


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at Vanderbilt University for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


[?]
Followed By

Follow this innovation



No one is following this innovation.

Organization
1849

Vanderbilt University


Profile
Related Tags

Find more innovations

February 11, 2009

7,783 members 17,070 innovations 152 organizations

Browse

William Garner, M.D., MPH - CEO of Urigen, N.A., Inc.

"The iBridge Network provides an important additional pathway for entrepreneurs to access university innovations that may otherwise have been lost. The transparency of this pathway between entrepreneurs..."  read more...